Can I Take Omega-3 (EPA/DHA) with Rapamycin (Sirolimus)?

How Sirolimus Works and Why Supplements Matter

Sirolimus is a macrolide immunosuppressant that binds FKBP-12 and inhibits the mechanistic target of rapamycin complex 1 (mTORC1). The FDA approved sirolimus (brand name Rapamune) in 1999 for prophylaxis of renal allograft rejection, and it is now used off-label in a growing longevity medicine context at lower once-weekly doses [1].

The drug has a narrow therapeutic index and a long half-life of approximately 62 hours in stable renal transplant recipients [1]. Small changes in absorption, metabolism, or protein binding can shift trough concentrations meaningfully. That is why the prescribing information dedicates an entire section to drug and food interactions, specifically calling out grapefruit juice and strong CYP3A4 modulators.

Why the Supplement Question Keeps Coming Up

Patients on sirolimus, whether post-transplant or in longevity programs, frequently ask about fish oil because omega-3s address two conditions that sirolimus itself can worsen. Sirolimus raises triglycerides in a dose-dependent manner in up to 38 to 45% of transplant recipients, based on data from the key Phase III trial supporting Rapamune approval [1]. Omega-3 fatty acids are among the most evidence-backed non-statin agents for hypertriglyceridemia.

The question is not simply "will this hurt me?" It is also "could this actually help me?"

The mTOR Angle

Animal data suggest omega-3 fatty acids may themselves modulate mTOR signaling. A 2018 study in Frontiers in Physiology found that DHA attenuated mTORC1 activity in skeletal muscle cells under nutrient-excess conditions [2]. Whether that translates to a clinically meaningful additive or competing effect on mTOR inhibition in humans taking 1 to 6 mg sirolimus weekly is unknown. No human trial has examined this question directly.

Pharmacokinetic Interaction: Is There One?

The short answer is: not a clinically significant one detected in current evidence.

Sirolimus is metabolized almost entirely by CYP3A4 and to a lesser extent by P-glycoprotein (P-gp) efflux in the gut wall and liver. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin) can raise sirolimus blood levels by 4- to 11-fold [1]. Strong inducers (rifampin) can lower levels by 82% [1].

Omega-3s and CYP3A4

Omega-3 fatty acids, including prescription formulations such as icosapentaenoic acid ethyl ester (Vascepa, 4 g/day) and EPA/DHA ethyl esters (Lovaza, 4 g/day), are not classified as meaningful CYP3A4 inhibitors or inducers in the FDA prescribing information for either product [3][4]. The Natural Medicines Database rates the pharmacokinetic interaction between fish oil and sirolimus as having insufficient evidence to quantify, placing it below the threshold of a clinically recognized drug-drug interaction.

A 2010 study in Clinical Pharmacokinetics reviewed the effect of dietary fat on sirolimus bioavailability and found that a high-fat meal increased sirolimus AUC by approximately 35% compared to fasting [5]. Since omega-3 supplements are a fat source, taking them alongside sirolimus could theoretically alter absorption, but the magnitude is small relative to the meal effect already described in the label. Standard practice is to take sirolimus consistently with or without food every day, not to avoid fat specifically.

P-gp Considerations

Neither EPA nor DHA has demonstrated clinically significant P-gp inhibition in human pharmacokinetic studies. A 2016 review in Drug Metabolism and Disposition noted that fatty acids can modulate transporter expression in rodent models but that the human clinical relevance remains unestablished [6]. In the absence of human PK interaction data, the conservative interpretation is that omega-3s at over-the-counter or prescription doses do not meaningfully alter sirolimus blood concentrations through this mechanism.

Pharmacodynamic Interactions: Where the Real Concerns Live

Two overlapping biological effects deserve attention.

Antiplatelet and Bleeding Risk

Sirolimus does not directly inhibit platelet aggregation, but it is used in drug-eluting stents where its antiproliferative effects on smooth muscle cells require concurrent antiplatelet therapy. In that specific context, adding fish oil raises the question of stacking antiplatelet agents.

More broadly, EPA and DHA reduce platelet aggregation through multiple mechanisms: incorporation into platelet membrane phospholipids, competition with arachidonic acid for thromboxane A2 synthesis, and increased production of anti-aggregatory prostacyclin [7]. A 2020 meta-analysis in the Journal of the American Heart Association (k=17 RCTs, N=7,601) found that omega-3 supplementation at doses of 1 to 4 g/day was associated with a modestly increased risk of atrial fibrillation (HR 1.37, 95% CI 1.22 to 1.54) at higher doses, though the bleeding risk signal was not consistently significant across all trials [8].

For a post-transplant patient who may already be taking mycophenolate, corticosteroids, or tacrolimus alongside sirolimus, adding omega-3s is unlikely to cause serious bleeding on its own. For a patient on concurrent anticoagulation (warfarin, apixaban), the combination warrants physician awareness, not necessarily prohibition.

Triglyceride Effects: Opposing and Complementary

Sirolimus-associated hypertriglyceridemia is well-documented. In a multicenter randomized trial comparing sirolimus-based versus calcineurin inhibitor-based regimens in 430 de novo renal transplant patients, sirolimus recipients had significantly higher triglyceride levels at 12 months (mean 212 mg/dL vs. 156 mg/dL, P<0.001) [9].

Prescription omega-3 products address this directly. In the MARINE trial (N=229), icosapentaenoic acid ethyl ester 4 g/day reduced triglycerides by 33.1% versus placebo in patients with severe hypertriglyceridemia (>500 mg/dL) [10]. In patients with moderately elevated triglycerides (200 to 499 mg/dL), the ANCHOR trial (N=702) showed a 21.5% reduction with the same dose [11].

The combined pharmacodynamic effect, sirolimus raising triglycerides and omega-3s lowering them, is not necessarily dangerous. It may be clinically useful. However, a prescribing physician needs to know both agents are on board so that the lipid response is interpreted correctly and neither drug is over- or under-titrated based on incomplete information.

HealthRX Clinical Decision Framework: Omega-3 + Sirolimus

| Scenario | Risk Level | Recommended Action | |---|---|---| | Transplant patient, no anticoagulation, sirolimus stable | Low | Inform transplant team; check trough and lipids at 6 weeks | | Longevity/off-label user, weekly dosing, no anticoagulation | Low | Document with prescribing clinician; baseline lipid panel | | Any patient on concurrent warfarin or DOAC | Moderate | Physician review before starting omega-3; INR check within 2 weeks if on warfarin | | Patient with sirolimus-induced hypertriglyceridemia >500 mg/dL | Potentially beneficial | Formal evaluation for prescription omega-3 (Vascepa or Lovaza) | | Recent surgical procedure or active bleeding risk | Moderate-High | Defer omega-3 supplementation; discuss timing with surgeon |

Sirolimus-Specific Monitoring When Adding Omega-3s

Trough Levels

The Rapamune prescribing information specifies a target trough range of 4 to 12 ng/mL for maintenance dosing in low-to-moderate immunologic risk renal transplant patients [1]. The American Society of Transplantation and transplant nephrology guidelines recommend trough monitoring every 3 to 6 months in stable patients, and after any addition of an agent that could interact with CYP3A4 [12].

Because omega-3s are not recognized CYP3A4 modulators, a single extra trough check within 4 to 6 weeks of starting them is a conservative but defensible precaution rather than a strict requirement. If the trough comes back within range and stable, the monitoring interval can return to the routine schedule.

Lipid Panel

A fasting lipid panel is appropriate at baseline and 6 to 8 weeks after initiating omega-3 supplementation. Triglycerides should be the primary endpoint. If the prescribing team is also managing sirolimus-associated dyslipidemia with a statin, they need to know that omega-3s have been added so the statin dose decision is not influenced by an unacknowledged confound.

Platelet Function and CBC

Routine platelet function testing is not standard in this combination. A complete blood count at baseline is reasonable if the patient is post-transplant and on mycophenolate, which can itself cause thrombocytopenia. Adding omega-3s in that setting warrants awareness of the full antiplatelet stack.

Dosing Considerations for Both Agents

What Dose of Omega-3 Is Relevant?

Over-the-counter fish oil capsules typically contain 300 to 600 mg of combined EPA/DHA per capsule, with consumers often taking 1 to 3 capsules daily (300 mg to 1.8 g EPA/DHA per day). Prescription formulations supply 4 g/day.

The antiplatelet and triglyceride effects are dose-dependent. At 1 g/day or below, the pharmacodynamic signal is small. At 4 g/day (prescription level), the triglyceride lowering is clinically significant and the antiplatelet contribution becomes more relevant.

A patient asking about a standard over-the-counter fish oil at 1,000 mg/day is in a meaningfully different risk category than a patient taking Vascepa 4 g/day alongside anticoagulation.

Sirolimus Dosing Context

FDA-approved transplant dosing typically starts at 6 mg loading dose followed by 2 mg/day maintenance, adjusted to trough [1]. Off-label longevity protocols, sometimes referenced in peer-reviewed discussions of aging biology, typically use 1 to 6 mg once weekly. The PEARL trial protocol and Matt Kaeberlein's Dog Aging Project have used 0.05 mg/kg/week in canine models, but no RCT has established a standard human longevity dose [13].

The interaction profile at low once-weekly longevity doses may differ from daily transplant dosing simply because the exposure curve is different. Trough levels in weekly longevity dosing are typically undetectable by standard assays. That context matters: a pharmacodynamic interaction with omega-3s at sub-nanogram sirolimus concentrations is biologically implausible.

What the Guidelines Say

The FDA prescribing information for Rapamune (sirolimus) does not list omega-3 fatty acids as a contraindicated or cautioned co-administration [1]. The prescribing information for Vascepa (icosapentaenoic acid) similarly does not list sirolimus as a recognized interaction [3].

The American Association of Clinical Endocrinology (AACE) 2022 clinical practice guidelines on dyslipidemia recommend prescription omega-3 fatty acids for patients with triglycerides above 500 mg/dL, without carving out an exception for patients on sirolimus [14]. The Kidney Disease Improving Global Outcomes (KDIGO) 2009 guidelines on lipid management in chronic kidney disease transplant recipients note that statin therapy is first-line but do not prohibit omega-3 use [15].

As the Rapamune prescribing information states directly: "Because of the potential for interaction, dietary supplements containing St. John's Wort (Hypericum perforatum) and grapefruit products should be avoided." [1] Omega-3s are not mentioned. That omission reflects the absence of a recognized clinically significant interaction, not a data gap that should trigger alarm.

Practical Guidance for Patients Already Taking Both

If you are already taking omega-3 supplements alongside sirolimus and have not told your prescribing team, the right move is disclosure, not discontinuation. Abrupt changes to sirolimus-adjacent therapies are more new than a stable documented combination.

Tell your transplant nephrologist, longevity physician, or primary care prescriber the specific dose of omega-3 you are taking, the brand, and how long you have been on it. Bring a bottle or a photo of the label so the EPA/DHA content per dose is clear.

If your most recent sirolimus trough was within the therapeutic range and your lipids have been stable, the clinical picture is already reassuring. Your physician may simply add the omega-3 to your medication list and increase lipid monitoring frequency for one cycle.

Patients on warfarin alongside sirolimus who are adding omega-3s should have an INR checked within two weeks given the theoretical additive effect on coagulation, even though the magnitude of the omega-3 effect on INR is generally small in clinical studies.

Off-Label Longevity Use: A Different Risk Calculus

The growing use of low-dose weekly sirolimus in adults seeking longevity benefits operates largely outside the transplant pharmacovigilance infrastructure. In transplant medicine, troughs are checked regularly and nephrology teams are alert to drug interactions. In longevity medicine, oversight varies widely.

A 2023 review in Nature Aging by Blagosklonny and colleagues discussed the rationale for low-dose rapamycin in aging, noting the need for prospective safety monitoring [16]. Without routine trough monitoring in the longevity context, adding omega-3s introduces a very small but unquantified pharmacodynamic unknown.

The conservative recommendation for longevity users: inform your prescribing clinician about all supplements, get a baseline lipid panel before starting omega-3s, and repeat at 3 months. Given that sirolimus trough levels in once-weekly low-dose regimens may be undetectable, the primary monitoring concern shifts entirely to the pharmacodynamic domain, meaning lipids and platelet status rather than drug blood levels.